Nephrology Medical News about renal cell carcinoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Analysis of PTEN and HIF-1[alpha] and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-[alpha]
Cancer, 06/16/09

Figlin RA et al. - The baseline status of the molecular markers PTEN and HIF1 alpha did not correlate with efficacy in renal cell carcinoma patients treated with temsirolimus versus IFN. Patients demonstrated OS and progression-free survival benefit when treated with temsirolimus regardless of PTEN and HIF1 alpha status.

Exclusive Author Commentary
Robert A. Figlin, 06/16/09

Although this study did not demonstrate a correlation with response and survival for the biomarkers tested, it remains a high priority for all trials in renal cell carcinoma to identify and test the validity of a biomarker to predict biologic behavior.

<< Previous
Activated extracellular signal-regulated kinase is an independent...

Next >>
AMA: Better care guidelines would slow health spending